Leary Siobhan M, Thompson Alan J
NMR Research Unit, Institute of Neurology, University College London, Queen Square, WC1N 3BG, London, UK.
J Neurol Sci. 2003 Feb 15;206(2):215-6. doi: 10.1016/s0022-510x(02)00350-7.
There is currently no disease-modifying treatment proven to be of efficacy in primary progressive multiple sclerosis (PPMS). However, a number of therapeutic trials have recently been specifically designed for this group. These include a randomised controlled trial of interferon beta-1a which is discussed here. It is hoped that therapeutics in primary progressive multiple sclerosis will continue to expand and effective therapeutic agents will be developed.